Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
EMERYVILLE, Calif., Sept. 09, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that its new Vice President of Corporate Communications and Investor Relations, Martin Forrest, received a grant of an option to purchase 31,875 shares of the company's common stock, at a per share exercise price of $16.13, the closing trading price on September 8, 2016, and 5,313 restricted stock units, pursuant to the terms of his employment agreement with Adamas. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly owned product candidate, for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company is also evaluating ADS-4101, an extended-release version of an FDA-approved single-agent compound for the treatment of epilepsy. In addition, under a license agreement with Forest Laboratories Holdings Limited, an indirect wholly owned subsidiary of Allergan plc., the company is eligible to receive royalties from Forest on sales of Namenda XR® and Namzaric™ beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.
For questions, please contact: Susan Lehner Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3567
